CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Robert Marcus
JPMorgan Chase & Co, Research Division

Good morning, everyone. I’m Robbie Marcus, the Med Tech Analyst at JPMorgan. Very happy to introduce our next company, CeriBell. We’ll have Jane Chao, the CEO, come up for a presentation followed by some Q&A. Jane?

Xingjuan Chao
Co-Founder, President, CEO & Director

Thank you, Robbie. Good morning, everyone. I’m very excited to share with you the overview of CeriBell and our 2025 accomplishment and 2026 plan. So at the highest level, CeriBell has developed a platform for neuromonitoring. It has the hardware that makes EEG or brainwave acquisition really easy and fast. So nurses can set up in a few minutes instead of waiting for specialized EEG technician that’s often hours and days. It also have the AI-powered algorithm called Clarity detecting multiple different neurological disorders.

Till today, our commercial effort has been 100% focused on seizure detection in Acute Care, and that is ICU and ED largely. And that in the U.S. alone translate into about more than $2 billion market opportunity. And this past year, we are guiding $87 million to $89 million, 34% year-over-year growth at 88% gross margin. 2025, we also made significant progress in expanding our market. So the TAM grow from $2 billion to $3.5 billion, I’ll walk you through, largely driven by expanding seizure to Pediatric and Neonate population as well as gaining FDA clearance on the first and only Delirium Detection.

Now I will focus on Seizure Detection in the Acute Care setting for the first half of this presentation. Seizures are very common in